Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px
Document › Details

Agilent Technologies Inc.. (2/12/13). "Press Release: Agilent Technologies and Sera Prognostics Enter Strategic Partnership to Develop Proteomic Assays for Fetal and Maternal Health". Santa Clara, CA & Salt Lake City, UT.

Organisation Organisation Sera Prognostics Inc.
Products Product prenatal proteomic test_o
  Product 2 6490 iFunnel Triple Quadrupole LC/MS system (Agilent)
Index term Index term Sera Prognostics–Agilent: proteomic prenatal tests, 201302– collab developm proteomic assays for early prediction of pregnancy complications
Persons Person Critchfield, Gregory C. (Sera Prognostics 201111– CEO before Board Chairman before Myriad Genetic Labs + BioTrove Inc)
  Person 2 Linney, Yvonne (Transcriptic 201510– COO before Agilent 200701)
     


Agilent Technologies Inc. (NYSE: A) and Sera Prognostics Inc., a women's health company, today announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications.

Sera Prognostics is currently developing a novel test for the early prediction of preterm birth risk using advanced proteomic science. Agilent is a leading provider of a wide range of analytical instrumentation, including liquid chromatography, mass spectrometry and automation systems.

"By providing pivotal information to physicians, Sera's preterm birth predictor is designed to address an unmet medical need for a reliable, early risk assessment that has the potential to help significantly improve the health of mothers and newborns, while materially reducing the costs of care," said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics. "Our partnership with Agilent provides Sera with access to advanced and innovative technologies designed to deliver on the promise of personalized medicine."

"Agilent and Sera Prognostics share the vision of applying the power of advanced proteomic technologies to address meaningful medical challenges," said Yvonne Linney, VP and general manager of Agilent's Life Science Solutions Division. "Agilent instrumentation is at the forefront of driving high-throughput workflows for sample preparation and mass-spec analysis that is critical in the field of proteomics."

As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilent's automated sample-preparation technologies for production.

The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis. To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilent's novel automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.


About Sera Prognostics, Inc.

Sera Prognostics is a private biotechnology company developing novel diagnostic tests designed for the early prediction of preterm birth and other pregnancy complications, so that personalized, effective care can be given. These innovative tests have the potential of improving the health of both mothers and infants. In November 2011, Sera completed a Series A financing round of $19.3 million to develop its ProNid preterm birth predictor. The company has assembled a strong management team and board of directors with significant clinical development and women's health-care diagnostic experience. Sera is currently completing the world's largest clinical biomarker study focused on the validation of its ProNid test for predicting the risk of preterm birth. Sera is located in Salt Lake City, Utah. For more information, visit www.seraprognostics.com.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.

# # #

Contact:

Eric Endicott, Agilent +1 408 553 2005
eric_endicott@agilent.com

Andrew Sauter, CFO, Sera Prognostics, Inc.
+ 801 990-0772
info@seraprognostics.com

Terri Clevenger, Continuum Health Communications, for Sera
+ 203 856-4326
tclevenger@continuumhealthcom.com

   
Record changed: 2016-03-19

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px